View Older Stories View More Recent Stories

Jan 6, 2026 09:41AM Ideaya Biosciences (IDYA) PT Raised to $60 at Truist Securities
Dec 12, 2025 09:16AM Citi Opens 90-Day Upside Catalyst Watch on Ideaya Biosciences (IDYA)
Dec 10, 2025 06:01AM IDEAYA Biosciences Announces IND Submission for IDE574
Dec 5, 2025 04:26PM GSK terminates collaboration agreement with IDEAYA Biosciences
Dec 1, 2025 06:00AM IDEAYA Biosciences receives FDA clearance for cancer drug trial
Nov 24, 2025 07:34AM Truist Securities Starts Ideaya Biosciences (IDYA) at Buy
Nov 4, 2025 06:26AM IDEAYA Biosciences (IDYA) Tops Q3 EPS by 133c
Oct 21, 2025 04:16AM Ideaya Biosciences (IDYA) PT Raised to $41 at RBC Capital
Oct 13, 2025 04:34AM Citizens Reiterates Market Outperform on Ideaya Biosciences (IDYA); Bullish on Darovasertib
Oct 7, 2025 07:53AM Citizens stays bullish on Ideaya ahead of ESMO update
Oct 4, 2025 04:00PM Why UBS says Q4 is eventful for SMID oncology stocks
Sep 23, 2025 08:53AM UBS Reiterates Buy Rating on Ideaya Biosciences (IDYA)
Sep 12, 2025 05:40AM Mizuho Reiterates Outperform Rating on Ideaya Biosciences (IDYA)
Sep 11, 2025 08:18AM RBC Capital on Biotech Shares: 'Company-Specific Volatility For Quality Names May Be Overdone'
Sep 9, 2025 09:19AM Ideaya Biosciences (IDYA) PT Raised to $38 at RBC Capital
Sep 9, 2025 08:53AM Cantor Fitzgerald Reiterates Overweight Rating on Ideaya Biosciences (IDYA)
Sep 9, 2025 07:00AM Ideaya Biosciences (IDYA) PT Raised to $30 at Leerink Partners
Sep 9, 2025 04:04AM Citizens JMP Reiterates Market Outperform Rating on Ideaya Biosciences (IDYA)
Sep 8, 2025 04:14AM Ideaya Biosciences (IDYA) PT Raised to $45 at Citizens JMP
Sep 4, 2025 03:54AM Barclays Starts Ideaya Biosciences (IDYA) at Overweight
Sep 4, 2025 03:33AM Citizens JMP Starts Ideaya Biosciences (IDYA) at Market Outperform
Sep 3, 2025 06:57AM Ideaya Biosciences (IDYA) PT Raised to $74 at JPMorgan
Sep 3, 2025 06:00AM IDEAYA Biosciences submits IND for PRMT5 inhibitor IDE892
Sep 2, 2025 06:01AM Servier licenses IDEAYA's uveal melanoma drug for $210 million upfront
Aug 18, 2025 06:01AM IDEAYA Biosciences schedules R&D day for September 8 in New York
Aug 5, 2025 06:23AM IDEAYA Biosciences (IDYA) Misses Q2 EPS by 9c
Aug 5, 2025 06:21AM IDEAYA Biosciences (IDYA) Misses Q2 EPS by 9c
Jul 30, 2025 06:40AM Ideaya Biosciences (IDYA) PT Lowered to $43 at Mizuho
Jul 22, 2025 01:01PM IDEAYA and Hengrui to present lung cancer drug data at conference
Jul 22, 2025 05:43AM TD Cowen Starts Ideaya Biosciences (IDYA) at Buy
Jul 10, 2025 06:29AM Goldman Sachs Resumes Ideaya Biosciences (IDYA) at Neutral
Jul 9, 2025 10:35AM Ideaya Biosciences (IDYA) PT Lowered to $30 at RBC Capital
Jun 26, 2025 06:23AM Wells Fargo Starts Ideaya Biosciences (IDYA) at Overweight
May 6, 2025 06:33AM IDEAYA Biosciences (IDYA) Misses Q1 EPS by 14c
May 6, 2025 06:01AM IDEAYA Biosciences (IDYA) Announces FDA IND-Clearance for IDE849
Apr 14, 2025 06:00AM IDEAYA Biosciences (IDYA) Announces Successful FDA Type D Meeting on Phase 3 Registrational Trial Design for Darovasertib
Mar 31, 2025 06:29AM IDEAYA Biosciences (IDYA) Receives US FDA Breakthrough Therapy Designation for Darovasertib Monotherapy in Neoadjuvant Uveal Melanoma
Feb 13, 2025 06:27AM IDEAYA Biosciences (IDYA) Misses Q4 EPS by 149c
Feb 13, 2025 06:04AM IDEAYA Biosciences (IDYA) Announces Further Gilead Sciences Clinical Study Collaboration Evaluating Combination of Trodelvy and IDE397
Feb 10, 2025 06:02AM IDEAYA Biosciences (IDYA) Appoints Joshua Bleharski as CFO
Jan 21, 2025 06:24AM BTIG Reiterates Buy Rating on Ideaya Biosciences (IDYA)
Jan 2, 2025 04:00PM Biotech outlook for 2025: Stifel
Dec 30, 2024 04:19AM BTIG Reiterates Buy Rating on Ideaya Biosciences (IDYA)
Dec 21, 2024 10:00AM RBC report: Biotech faces both uncertainty and growth opportunities in 2025
Dec 17, 2024 08:17AM RBC Capital on Ideaya Biosciences (IDYA): 'R&D Day Underscores Strengths & Expansive Pipeline'
Dec 16, 2024 06:04AM IDEAYA Biosciences (IDYA) Announces Development Candidate Nomination of IDE251
Dec 10, 2024 06:01AM IDEAYA (IDYA) Announces First-Patient-In for Phase 1 Clinical Trial Evaluating IDE161 in Combination with KEYTRUDA®
Nov 5, 2024 06:22AM Leerink Partners Downgrades Ideaya Biosciences (IDYA) to Market Perform
Nov 4, 2024 06:17AM IDEAYA Biosciences (IDYA) Tops Q3 EPS by 2c
Oct 25, 2024 06:01AM IDEAYA Biosciences (IDYA) Reports Positive Interim Phase 1 Expansion Data of IDE397
View More Recent Stories View Older Stories